Eur J Hosp Pharm 20:60 doi:10.1136/ejhpharm-2012-000218
  • Drug news

EMA approved new drugs: Photodynamic therapy for actinic keratosis

  1. Mark Nolan
  1. Correspondence to Dr Mark Nolan Pharm D, 246 Winslow Way Apt 201, Bainbridge Island, Washington 98110, USA; friendsofpills{at}

Actinic keratoses are superficial neoplasms that develop from sun-damaged skin and, if not treated, may progress to cutaneous squamous cell carcinoma. They tend to appear on the face, scalp, back of the hands, chest or other sun-exposed areas and often appear as flat, scaly, red or pink areas that may be easier to feel than see. According to Cancer Research UK, almost 100 000 cases of non-melanoma skin cancer are diagnosed in the UK each year. This makes it the most common type of cancer by far. This type of cancer also tends to be under-reported. Treatment typically consists of liquid nitrogen cryotherapy, surgical removal, topical 5-fluorouracil, imiquimod, ingenol mebutate, topical diclofenac, retinoids, dermabrasion, chemical peels and/or photodynamic therapy (PDT). Deciding which treatment to choose depends on the size, location and number of lesions. For most cases the inexpensive remedy of liquid nitrogen is the treatment of choice, while those …

EJHP blog

Analysis and discussion of the latest news, research findings and policy developments in hospital pharmacy.

Visit the blog >>

Free Sample

This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of EJHP.

View free sample issue >>

Email alerts

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article